Neutralization of MERS coronavirus through a scalable nanoparticle vaccine

Abstract MERS-CoV continues to cause human outbreaks, so far in 27 countries worldwide following the first registered epidemic in Saudi Arabia in 2012. In this study, we produced a nanovaccine based on virus-like particles (VLPs). VLPs are safe vaccine platforms as they lack any replication-competen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mona O. Mohsen, Dominik Rothen, Ina Balke, Byron Martina, Vilija Zeltina, Varghese Inchakalody, Zahra Gharailoo, Gheyath Nasrallah, Said Dermime, Kaspars Tars, Monique Vogel, Andris Zeltins, Martin F. Bachmann
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/75e90d2e660e4495962a2ced6e6426ae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:75e90d2e660e4495962a2ced6e6426ae
record_format	dspace
spelling	oai:doaj.org-article:75e90d2e660e4495962a2ced6e6426ae2021-12-02T19:02:27ZNeutralization of MERS coronavirus through a scalable nanoparticle vaccine10.1038/s41541-021-00365-w2059-0105https://doaj.org/article/75e90d2e660e4495962a2ced6e6426ae2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00365-whttps://doaj.org/toc/2059-0105Abstract MERS-CoV continues to cause human outbreaks, so far in 27 countries worldwide following the first registered epidemic in Saudi Arabia in 2012. In this study, we produced a nanovaccine based on virus-like particles (VLPs). VLPs are safe vaccine platforms as they lack any replication-competent genetic material, and are used since many years against hepatitis B virus (HBV), hepatitis E virus (HEV) and human papilloma virus (HPV). In order to produce a vaccine that is readily scalable, we genetically fused the receptor-binding motif (RBM) of MERS-CoV spike protein into the surface of cucumber-mosaic virus VLPs. The employed CuMVTT-VLPs represent a new immunologically optimized vaccine platform incorporating a universal T cell epitope derived from tetanus toxin (TT). The resultant vaccine candidate (mCuMVTT-MERS) is a mosaic particle and consists of unmodified wild type monomers and genetically modified monomers displaying RBM, co-assembling within E. coli upon expression. mCuMVTT-MERS vaccine is self-adjuvanted with ssRNA, a TLR7/8 ligand which is spontaneously packaged during the bacterial expression process. The developed vaccine candidate induced high anti-RBD and anti-spike antibodies in a murine model, showing high binding avidity and an ability to completely neutralize MERS-CoV/EMC/2012 isolate, demonstrating the protective potential of the vaccine candidate for dromedaries and humans.Mona O. MohsenDominik RothenIna BalkeByron MartinaVilija ZeltinaVarghese InchakalodyZahra GharailooGheyath NasrallahSaid DermimeKaspars TarsMonique VogelAndris ZeltinsMartin F. BachmannNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Mona O. Mohsen Dominik Rothen Ina Balke Byron Martina Vilija Zeltina Varghese Inchakalody Zahra Gharailoo Gheyath Nasrallah Said Dermime Kaspars Tars Monique Vogel Andris Zeltins Martin F. Bachmann Neutralization of MERS coronavirus through a scalable nanoparticle vaccine
description	Abstract MERS-CoV continues to cause human outbreaks, so far in 27 countries worldwide following the first registered epidemic in Saudi Arabia in 2012. In this study, we produced a nanovaccine based on virus-like particles (VLPs). VLPs are safe vaccine platforms as they lack any replication-competent genetic material, and are used since many years against hepatitis B virus (HBV), hepatitis E virus (HEV) and human papilloma virus (HPV). In order to produce a vaccine that is readily scalable, we genetically fused the receptor-binding motif (RBM) of MERS-CoV spike protein into the surface of cucumber-mosaic virus VLPs. The employed CuMVTT-VLPs represent a new immunologically optimized vaccine platform incorporating a universal T cell epitope derived from tetanus toxin (TT). The resultant vaccine candidate (mCuMVTT-MERS) is a mosaic particle and consists of unmodified wild type monomers and genetically modified monomers displaying RBM, co-assembling within E. coli upon expression. mCuMVTT-MERS vaccine is self-adjuvanted with ssRNA, a TLR7/8 ligand which is spontaneously packaged during the bacterial expression process. The developed vaccine candidate induced high anti-RBD and anti-spike antibodies in a murine model, showing high binding avidity and an ability to completely neutralize MERS-CoV/EMC/2012 isolate, demonstrating the protective potential of the vaccine candidate for dromedaries and humans.
format	article
author	Mona O. Mohsen Dominik Rothen Ina Balke Byron Martina Vilija Zeltina Varghese Inchakalody Zahra Gharailoo Gheyath Nasrallah Said Dermime Kaspars Tars Monique Vogel Andris Zeltins Martin F. Bachmann
author_facet	Mona O. Mohsen Dominik Rothen Ina Balke Byron Martina Vilija Zeltina Varghese Inchakalody Zahra Gharailoo Gheyath Nasrallah Said Dermime Kaspars Tars Monique Vogel Andris Zeltins Martin F. Bachmann
author_sort	Mona O. Mohsen
title	Neutralization of MERS coronavirus through a scalable nanoparticle vaccine
title_short	Neutralization of MERS coronavirus through a scalable nanoparticle vaccine
title_full	Neutralization of MERS coronavirus through a scalable nanoparticle vaccine
title_fullStr	Neutralization of MERS coronavirus through a scalable nanoparticle vaccine
title_full_unstemmed	Neutralization of MERS coronavirus through a scalable nanoparticle vaccine
title_sort	neutralization of mers coronavirus through a scalable nanoparticle vaccine
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/75e90d2e660e4495962a2ced6e6426ae
work_keys_str_mv	AT monaomohsen neutralizationofmerscoronavirusthroughascalablenanoparticlevaccine AT dominikrothen neutralizationofmerscoronavirusthroughascalablenanoparticlevaccine AT inabalke neutralizationofmerscoronavirusthroughascalablenanoparticlevaccine AT byronmartina neutralizationofmerscoronavirusthroughascalablenanoparticlevaccine AT vilijazeltina neutralizationofmerscoronavirusthroughascalablenanoparticlevaccine AT vargheseinchakalody neutralizationofmerscoronavirusthroughascalablenanoparticlevaccine AT zahragharailoo neutralizationofmerscoronavirusthroughascalablenanoparticlevaccine AT gheyathnasrallah neutralizationofmerscoronavirusthroughascalablenanoparticlevaccine AT saiddermime neutralizationofmerscoronavirusthroughascalablenanoparticlevaccine AT kasparstars neutralizationofmerscoronavirusthroughascalablenanoparticlevaccine AT moniquevogel neutralizationofmerscoronavirusthroughascalablenanoparticlevaccine AT andriszeltins neutralizationofmerscoronavirusthroughascalablenanoparticlevaccine AT martinfbachmann neutralizationofmerscoronavirusthroughascalablenanoparticlevaccine
_version_	1718377273566953472

Neutralization of MERS coronavirus through a scalable nanoparticle vaccine

Ejemplares similares